Adaptimmune Therapeutics PLC (ADAP)
0.6616
+0.02
(+3.93%)
USD |
NASDAQ |
Nov 22, 16:00
0.66
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Free Cash Flow: -56.05M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -56.05M |
| June 30, 2024 | -46.61M |
| March 31, 2024 | -138.26M |
| December 31, 2023 | -145.76M |
| September 30, 2023 | -131.64M |
| June 30, 2023 | -144.59M |
| March 31, 2023 | -149.80M |
| December 31, 2022 | -171.51M |
| September 30, 2022 | -40.24M |
| June 30, 2022 | -28.71M |
| March 31, 2022 | -11.74M |
| December 31, 2021 | 1.948M |
| September 30, 2021 | -158.39M |
| June 30, 2021 | -128.64M |
| March 31, 2021 | -120.84M |
| December 31, 2020 | -56.50M |
| September 30, 2020 | -39.19M |
| June 30, 2020 | -52.01M |
| Date | Value |
|---|---|
| March 31, 2020 | -61.76M |
| December 31, 2019 | -115.58M |
| September 30, 2019 | -134.34M |
| June 30, 2019 | -95.80M |
| March 31, 2019 | -97.22M |
| December 31, 2018 | -109.10M |
| September 30, 2018 | -100.48M |
| June 30, 2018 | -97.22M |
| March 31, 2018 | -87.59M |
| December 31, 2017 | -79.33M |
| September 30, 2017 | -60.59M |
| June 30, 2017 | -89.91M |
| March 31, 2017 | -80.64M |
| December 31, 2016 | -60.95M |
| September 30, 2016 | -63.53M |
| June 30, 2016 | -49.49M |
| March 31, 2016 | -45.42M |
Free Cash Flow Range, Past 5 Years
-171.51M
Minimum
Dec 2022
1.948M
Maximum
Dec 2021
-89.79M
Average
-88.67M
Median
Free Cash Flow Benchmarks
| Biodexa Pharmaceuticals PLC | -11.12M |
| NuCana PLC | -22.00M |
| Autolus Therapeutics PLC | -205.61M |
| TC BioPharm (Holdings) PLC | -15.84M |
| Verona Pharma PLC | -103.81M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -54.45M |
| Cash from Investing (Quarterly) | -66.02M |
| Cash from Financing (Quarterly) | 25.00M |
| Free Cash Flow Per Share (Quarterly) | -0.2146 |
| Free Cash Flow to Equity (Quarterly) | -79.80M |
| Free Cash Flow to Firm (Quarterly) | -54.89M |
| Free Cash Flow Yield | -34.41% |